Stephen Chrzanowski, MD, PhD

Articles by Stephen Chrzanowski, MD, PhD

Unmet Needs and Emerging Horizons for DMD

ByJohn F. Brandsema, MD,Stephen Chrzanowski, MD, PhD ,Divya Jayaraman, MD, PhD ,Aravindhan Veerapandiyan, MD

April 29th 2026

Duchenne trials accelerate with next-gen gene therapy, muscle-protecting drugs, and improved exon-skipping approaches—aiming for safer, longer-lasting benefits and easier dosing.

Emerging Therapies in DMD

ByJohn F. Brandsema, MD,Stephen Chrzanowski, MD, PhD ,Divya Jayaraman, MD, PhD ,Aravindhan Veerapandiyan, MD

April 29th 2026

Clinicians tailor Duchenne treatment over time, balancing steroid benefits, side effects, ambulation changes, and required monitoring for newer therapies and families.

DMD Management: Evolving Regimens and Real-World Adherence

ByJohn F. Brandsema, MD,Stephen Chrzanowski, MD, PhD ,Divya Jayaraman, MD, PhD ,Aravindhan Veerapandiyan, MD

April 22nd 2026

Clinicians tailor Duchenne steroid therapy over time—balancing benefits, side effects, and family capacity for monitoring newer treatments like gene therapy and givinostat.

DMD Treatment Algorithms: Initiating and Sequencing Therapies in New Patients

ByJohn F. Brandsema, MD,Stephen Chrzanowski, MD, PhD ,Divya Jayaraman, MD, PhD ,Aravindhan Veerapandiyan, MD

April 22nd 2026

Clinicians weigh vamorolone vs prednisone/deflazacort, tailoring growth and weight goals while managing tricky steroid switches and adrenal risks.

Steroid Transitions: Clinical Decision-Making Across the DMD Disease Course

ByJohn F. Brandsema, MD,Stephen Chrzanowski, MD, PhD ,Divya Jayaraman, MD, PhD ,Aravindhan Veerapandiyan, MD

April 15th 2026

Clinicians weigh vamorolone vs prednisone/deflazacort for young boys, balancing growth, weight, and adrenal safety during steroid transitions.

Evaluating a Newer Corticosteroid Option, Vamoralone, in DMD

ByJohn F. Brandsema, MD,Stephen Chrzanowski, MD, PhD ,Divya Jayaraman, MD, PhD ,Aravindhan Veerapandiyan, MD

April 15th 2026

Explore today’s Duchenne muscular dystrophy treatment options, from corticosteroids and givinostat to gene therapy and exon skipping, plus evolving dosing debates.